These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 17214717)

  • 1. Clinical study with allogeneic cultured dermal substitutes for chronic leg ulcers.
    Yonezawa M; Tanizaki H; Inoguchi N; Ishida M; Katoh M; Tachibana T; Miyachi Y; Kubo K; Kuroyanagi Y
    Int J Dermatol; 2007 Jan; 46(1):36-42. PubMed ID: 17214717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of allogeneic cultured dermal substitutes for intractable skin ulcers after tumor resection.
    Moroi Y; Fujita S; Fukagawa S; Mashino T; Goto T; Masuda T; Urabe K; Kubo K; Matsui H; Kagawa S; Kuroyanagi Y; Furue M
    Eur J Dermatol; 2004; 14(3):172-6. PubMed ID: 15246944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective treatment of intractable skin ulcers using allogeneic cultured dermal substitutes in patients with systemic lupus erythematosus.
    Toyozawa S; Yamamoto Y; Kishioka A; Yonei N; Kanazawa N; Matsumoto Y; Kuroyanagi Y; Furukawa F
    Eur J Dermatol; 2009; 19(6):594-6. PubMed ID: 19666399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: a case of pyoderma gangrenosum with intractable leg ulcers treated by allogeneic cultured dermal substitutes.
    Toyozawa S; Yamamoto Y; Nishide T; Kishioka A; Kanazawa N; Matsumoto Y; Kuroyanagi Y; Furukawa F
    Dermatol Online J; 2008 Nov; 14(11):17. PubMed ID: 19094855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of full-thickness skin defect with concomitant grafting of 6-fold extended mesh auto-skin and allogeneic cultured dermal substitute.
    Kashiwa N; Ito O; Ueda T; Kubo K; Matsui H; Kuroyanagi Y
    Artif Organs; 2004 May; 28(5):444-50. PubMed ID: 15113338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous full-thickness skin substitute for healing chronic wounds.
    Gibbs S; van den Hoogenband HM; Kirtschig G; Richters CD; Spiekstra SW; Breetveld M; Scheper RJ; de Boer EM
    Br J Dermatol; 2006 Aug; 155(2):267-74. PubMed ID: 16882162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of banking system for allogeneic cultured dermal substitute.
    Kuroyanagi Y; Kubo K; Matsui H; Kim HJ; Numari S; Mabuchi Y; Kagawa S
    Artif Organs; 2004 Jan; 28(1):13-21. PubMed ID: 14720283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An allogeneic cultured dermal substitute suitable for treating intractable skin ulcers and large skin defects prior to autologous skin grafting: three case reports.
    Hasegawa T; Suga Y; Mizoguchi M; Muramatsu S; Mizuno Y; Ogawa H; Kubo K; Kuroyanagi Y
    J Dermatol; 2005 Sep; 32(9):715-20. PubMed ID: 16361714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of cytokines released from fibroblasts in cultured dermal substitute.
    Kubo K; Kuroyanagi Y
    Artif Organs; 2005 Oct; 29(10):845-9. PubMed ID: 16185348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic wound healing by fetal cell therapy may be explained by differential gene profiling observed in fetal versus old skin cells.
    Ramelet AA; Hirt-Burri N; Raffoul W; Scaletta C; Pioletti DP; Offord E; Mansourian R; Applegate LA
    Exp Gerontol; 2009 Mar; 44(3):208-18. PubMed ID: 19049860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of intractable skin ulcers caused by vascular insufficiency with allogeneic cultured dermal substitute: a report of eight cases.
    Taniguchi T; Amoh Y; Tanabe K; Katsuoka K; Kuroyanagi Y
    J Artif Organs; 2012 Mar; 15(1):77-82. PubMed ID: 21861088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EpiDex® Swiss field trial 2004-2008.
    Ortega-Zilic N; Hunziker T; Läuchli S; Mayer DO; Huber C; Baumann Conzett K; Sippel K; Borradori L; French LE; Hafner J
    Dermatology; 2010; 221(4):365-72. PubMed ID: 21071921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Regenerative medicine for skin].
    Kuroyanagi Y
    Nihon Rinsho; 2003 Mar; 61(3):427-31. PubMed ID: 12701169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The possibility of long-term cryopreservation of cultured dermal substitute.
    Kubo K; Kuroyanagi Y
    Artif Organs; 2005 Oct; 29(10):800-5. PubMed ID: 16185341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advances in regenerative medicine for skin].
    Kuroyanagi Y
    Nihon Ronen Igakkai Zasshi; 2005 Nov; 42(6):609-15. PubMed ID: 16408496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial of allogeneic cultured dermal substitutes for intractable skin ulcers of the lower leg.
    Yamada N; Uchinuma E; Kuroyanagi Y
    J Artif Organs; 2008; 11(2):100-3. PubMed ID: 18604614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wound-healing factors secreted by epidermal keratinocytes and dermal fibroblasts in skin substitutes.
    Spiekstra SW; Breetveld M; Rustemeyer T; Scheper RJ; Gibbs S
    Wound Repair Regen; 2007; 15(5):708-17. PubMed ID: 17971017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue-engineered product: allogeneic cultured dermal substitute composed of spongy collagen with fibroblasts.
    Kuroyanagi Y; Yamada N; Yamashita R; Uchinuma E
    Artif Organs; 2001 Mar; 25(3):180-6. PubMed ID: 11284884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Regenerative medicine for skin].
    Kuroyanagi Y
    Nihon Ronen Igakkai Zasshi; 2006 May; 43(3):326-9. PubMed ID: 16813088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency rhythmic electrical modulation system in the treatment of chronic painful leg ulcers.
    Janković A; Binić I
    Arch Dermatol Res; 2008 Aug; 300(7):377-83. PubMed ID: 18629524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.